ROIV / Roivant Sciences garners interest for multi-billion bowel drug - Bloomberg

Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a more_horizontal

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. more_horizontal

Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-s more_horizontal

Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company's future. The shares surged more_horizontal

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, more_horizontal

Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter f more_horizontal

Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant invest more_horizontal

Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's infl more_horizontal